CD79A and malaria: The present study expanded on the prior study by evaluating association of antibodies in this cohort with risk of clinical malaria over 10 year follow-up in three age groups (children < 5 years of age, children 5–14 years of age, and individuals ≥ 15 years of age) and with testing of not only IgG antibodies, but IgG1, IgG3, IgM and IgA antibodies to 16 vaccine-candidate antigens from three stages of malaria parasite life cycle in human host including Pfs230, a sexual stage antigen.